<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p157" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_157{left:35px;bottom:24px;letter-spacing:-0.34px;word-spacing:0.13px;}
#t2_157{left:306px;bottom:30px;}
#t3_157{left:313px;bottom:24px;letter-spacing:0.16px;}
#t4_157{left:346px;bottom:30px;}
#t5_157{left:351px;bottom:24px;letter-spacing:-0.16px;word-spacing:-0.22px;}
#t6_157{left:517px;bottom:30px;}
#t7_157{left:524px;bottom:24px;letter-spacing:-0.28px;word-spacing:-0.09px;}
#t8_157{left:288px;bottom:860px;letter-spacing:0.11px;word-spacing:-0.55px;}
#t9_157{left:288px;bottom:829px;letter-spacing:0.27px;word-spacing:-0.69px;}
#ta_157{left:1115px;bottom:27px;letter-spacing:0.23px;}
#tb_157{left:35px;bottom:777px;letter-spacing:0.13px;word-spacing:0.06px;}
#tc_157{left:35px;bottom:754px;letter-spacing:0.13px;word-spacing:0.05px;}
#td_157{left:285px;bottom:761px;letter-spacing:0.06px;}
#te_157{left:35px;bottom:713px;letter-spacing:0.23px;word-spacing:-1.28px;}
#tf_157{left:193px;bottom:713px;letter-spacing:0.13px;word-spacing:-0.76px;}
#tg_157{left:35px;bottom:690px;letter-spacing:0.13px;word-spacing:0.05px;}
#th_157{left:35px;bottom:667px;letter-spacing:0.06px;word-spacing:0.12px;}
#ti_157{left:35px;bottom:645px;letter-spacing:0.26px;word-spacing:-0.08px;}
#tj_157{left:35px;bottom:622px;letter-spacing:0.16px;word-spacing:0.02px;}
#tk_157{left:35px;bottom:599px;letter-spacing:0.2px;word-spacing:-0.8px;}
#tl_157{left:35px;bottom:575px;letter-spacing:0.2px;word-spacing:-0.01px;}
#tm_157{left:215px;bottom:583px;letter-spacing:0.1px;}
#tn_157{left:260px;bottom:575px;letter-spacing:0.14px;word-spacing:0.05px;}
#to_157{left:35px;bottom:552px;letter-spacing:0.16px;word-spacing:-0.34px;}
#tp_157{left:35px;bottom:529px;letter-spacing:0.09px;word-spacing:0.1px;}
#tq_157{left:35px;bottom:506px;letter-spacing:0.1px;word-spacing:0.09px;}
#tr_157{left:35px;bottom:482px;letter-spacing:0.2px;word-spacing:-0.02px;}
#ts_157{left:35px;bottom:459px;letter-spacing:0.03px;}
#tt_157{left:104px;bottom:467px;letter-spacing:0.1px;}
#tu_157{left:149px;bottom:459px;letter-spacing:0.06px;word-spacing:0.13px;}
#tv_157{left:35px;bottom:436px;letter-spacing:0.08px;word-spacing:0.11px;}
#tw_157{left:35px;bottom:413px;letter-spacing:0.12px;word-spacing:0.07px;}
#tx_157{left:35px;bottom:390px;letter-spacing:0.1px;word-spacing:0.08px;}
#ty_157{left:35px;bottom:366px;letter-spacing:-0.02px;word-spacing:0.36px;}
#tz_157{left:491px;bottom:366px;letter-spacing:0.1px;word-spacing:0.08px;}
#t10_157{left:35px;bottom:343px;letter-spacing:0.22px;word-spacing:-0.03px;}
#t11_157{left:209px;bottom:343px;letter-spacing:0.13px;word-spacing:0.06px;}
#t12_157{left:35px;bottom:320px;letter-spacing:0.09px;}
#t13_157{left:110px;bottom:327px;letter-spacing:0.12px;}
#t14_157{left:199px;bottom:320px;letter-spacing:0.06px;word-spacing:0.12px;}
#t15_157{left:35px;bottom:297px;letter-spacing:0.14px;word-spacing:-0.96px;}
#t16_157{left:35px;bottom:273px;letter-spacing:0.16px;word-spacing:0.03px;}
#t17_157{left:522px;bottom:281px;letter-spacing:-0.01px;}
#t18_157{left:35px;bottom:233px;letter-spacing:0.09px;word-spacing:0.1px;}
#t19_157{left:35px;bottom:210px;letter-spacing:0.14px;word-spacing:0.05px;}
#t1a_157{left:387px;bottom:217px;letter-spacing:0.1px;}
#t1b_157{left:433px;bottom:210px;letter-spacing:-0.24px;word-spacing:0.42px;}
#t1c_157{left:35px;bottom:187px;letter-spacing:0.13px;word-spacing:-0.74px;}
#t1d_157{left:35px;bottom:163px;letter-spacing:0.27px;}
#t1e_157{left:64px;bottom:171px;letter-spacing:0.06px;}
#t1f_157{left:130px;bottom:163px;letter-spacing:0.18px;word-spacing:-0.36px;}
#t1g_157{left:35px;bottom:140px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1h_157{left:35px;bottom:117px;letter-spacing:0.09px;word-spacing:0.1px;}
#t1i_157{left:35px;bottom:94px;letter-spacing:-0.03px;word-spacing:0.22px;}
#t1j_157{left:35px;bottom:71px;letter-spacing:0.11px;word-spacing:-0.74px;}
#t1k_157{left:252px;bottom:78px;letter-spacing:-0.01px;}
#t1l_157{left:274px;bottom:71px;word-spacing:-1.05px;}
#t1m_157{left:618px;bottom:777px;letter-spacing:0.11px;word-spacing:-0.74px;}
#t1n_157{left:618px;bottom:754px;letter-spacing:0.16px;word-spacing:0.03px;}
#t1o_157{left:618px;bottom:731px;letter-spacing:0.08px;word-spacing:0.1px;}
#t1p_157{left:618px;bottom:707px;letter-spacing:0.12px;word-spacing:0.06px;}
#t1q_157{left:618px;bottom:684px;word-spacing:-1.05px;}
#t1r_157{left:786px;bottom:692px;letter-spacing:0.06px;}
#t1s_157{left:852px;bottom:684px;letter-spacing:-0.02px;word-spacing:-1.02px;}
#t1t_157{left:618px;bottom:661px;letter-spacing:0.15px;word-spacing:0.04px;}
#t1u_157{left:618px;bottom:638px;letter-spacing:0.3px;}
#t1v_157{left:666px;bottom:645px;letter-spacing:0.1px;}
#t1w_157{left:710px;bottom:638px;letter-spacing:0.08px;word-spacing:-0.31px;}
#t1x_157{left:618px;bottom:614px;letter-spacing:0.11px;word-spacing:0.08px;}
#t1y_157{left:618px;bottom:591px;letter-spacing:0.05px;word-spacing:0.14px;}
#t1z_157{left:618px;bottom:552px;letter-spacing:0.12px;word-spacing:-0.94px;}
#t20_157{left:618px;bottom:529px;letter-spacing:0.08px;word-spacing:0.11px;}
#t21_157{left:618px;bottom:506px;letter-spacing:0.09px;word-spacing:0.1px;}
#t22_157{left:618px;bottom:482px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t23_157{left:758px;bottom:490px;letter-spacing:-0.01px;}
#t24_157{left:781px;bottom:482px;letter-spacing:0.05px;word-spacing:0.14px;}
#t25_157{left:618px;bottom:459px;letter-spacing:0.08px;word-spacing:0.11px;}
#t26_157{left:1028px;bottom:467px;letter-spacing:-0.01px;}
#t27_157{left:1051px;bottom:459px;letter-spacing:0.22px;word-spacing:-0.04px;}
#t28_157{left:618px;bottom:436px;letter-spacing:0.04px;word-spacing:0.25px;}
#t29_157{left:618px;bottom:413px;letter-spacing:0.14px;word-spacing:-1.18px;}
#t2a_157{left:775px;bottom:420px;letter-spacing:-0.01px;}
#t2b_157{left:797px;bottom:413px;letter-spacing:0.09px;word-spacing:-0.73px;}
#t2c_157{left:618px;bottom:390px;letter-spacing:0.08px;word-spacing:0.1px;}
#t2d_157{left:618px;bottom:366px;letter-spacing:0.1px;word-spacing:-0.97px;}
#t2e_157{left:957px;bottom:366px;}
#t2f_157{left:973px;bottom:366px;letter-spacing:0.06px;word-spacing:-0.49px;}
#t2g_157{left:618px;bottom:343px;letter-spacing:0.12px;word-spacing:0.07px;}
#t2h_157{left:618px;bottom:320px;letter-spacing:0.2px;word-spacing:-0.01px;}
#t2i_157{left:618px;bottom:297px;letter-spacing:0.16px;word-spacing:0.02px;}
#t2j_157{left:618px;bottom:273px;letter-spacing:0.16px;word-spacing:0.03px;}
#t2k_157{left:618px;bottom:250px;letter-spacing:0.1px;word-spacing:-0.53px;}
#t2l_157{left:618px;bottom:227px;letter-spacing:0.01px;word-spacing:0.18px;}
#t2m_157{left:618px;bottom:204px;letter-spacing:0.04px;word-spacing:0.15px;}
#t2n_157{left:618px;bottom:181px;letter-spacing:0.05px;word-spacing:0.14px;}
#t2o_157{left:618px;bottom:157px;letter-spacing:0.09px;word-spacing:0.1px;}
#t2p_157{left:1043px;bottom:165px;letter-spacing:-0.01px;}
#t2q_157{left:1066px;bottom:157px;letter-spacing:0.03px;word-spacing:0.14px;}
#t2r_157{left:618px;bottom:134px;letter-spacing:0.13px;word-spacing:-1.17px;}
#t2s_157{left:618px;bottom:111px;letter-spacing:0.15px;word-spacing:0.04px;}
#t2t_157{left:618px;bottom:88px;letter-spacing:0.14px;word-spacing:0.05px;}
#t2u_157{left:618px;bottom:64px;letter-spacing:0.13px;word-spacing:0.06px;}
#t2v_157{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_157{font-size:10px;font-family:ArialMT_5tg;color:#000;}
.s1_157{font-size:6px;font-family:ArialMT_5tg;color:#000;}
.s2_157{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_157{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_157{font-size:17px;font-family:ArialMT_5tg;color:#000;}
.s5_157{font-size:11px;font-family:ArialMT_5tg;color:#000;}
.s6_157{font-size:17px;font-family:Arial-ItalicMT_kb;color:#000;}
.s7_157{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts157" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-ItalicMT_kb;
	src: url("fonts/Arial-ItalicMT_kb.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

</style>
<div id="pg157Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg157" style="-webkit-user-select: none;"><object width="1210" height="935" data="157/157.svg" type="image/svg+xml" id="pdf157" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_157" class="t s0_157">Version 4.2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_157" class="t s1_157">© </span>
<span id="t3_157" class="t s0_157">(NCCN </span>
<span id="t4_157" class="t s1_157">© </span>
<span id="t5_157" class="t s0_157">), All rights reserved. NCCN Guidelines </span>
<span id="t6_157" class="t s1_157">® </span>
<span id="t7_157" class="t s0_157">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_157" class="t s2_157">NCCN Guidelines Version 4.2024 </span>
<span id="t9_157" class="t s2_157">Head and Neck Cancers </span>
<span id="ta_157" class="t s3_157">MS-16 </span>
<span id="tb_157" class="t s4_157">advanced form of CRT permitting more precise cancer targeting while </span>
<span id="tc_157" class="t s4_157">reducing dose to normal tissues. </span>
<span id="td_157" class="t s5_157">154,195-198 </span>
<span id="te_157" class="t s6_157">IMRT dose painting, </span><span id="tf_157" class="t s4_157">also known as SIB, refers to the method of assigning </span>
<span id="tg_157" class="t s4_157">different dose levels to different anatomic areas. These areas are all </span>
<span id="th_157" class="t s4_157">simultaneously irradiated within the same treatment fraction but receive </span>
<span id="ti_157" class="t s4_157">different prescribed doses (eg, 2.0 Gy/fraction to gross tumor, 1.6 </span>
<span id="tj_157" class="t s4_157">Gy/fraction to neck at risk for microscopic tumor, &lt;1.0 Gy/fraction to </span>
<span id="tk_157" class="t s4_157">parotid gland) resulting in different total doses to the different targets (eg, </span>
<span id="tl_157" class="t s4_157">70 Gy, 56 Gy, &lt;26 Gy). </span>
<span id="tm_157" class="t s5_157">199,200 </span>
<span id="tn_157" class="t s4_157">Although dose painting has been used to </span>
<span id="to_157" class="t s4_157">improve the specificity of radiation delivery to tumors and thereby reduce </span>
<span id="tp_157" class="t s4_157">unwanted radiation of uninvolved areas, hot spots associated with higher </span>
<span id="tq_157" class="t s4_157">toxicity can occur within large tumor targets due to the increasing </span>
<span id="tr_157" class="t s4_157">heterogeneity of dose distribution that occurs when prescribing to large </span>
<span id="ts_157" class="t s4_157">volumes. </span>
<span id="tt_157" class="t s5_157">200,201 </span>
<span id="tu_157" class="t s4_157">An alternative to the dose painting or SIB approach is to </span>
<span id="tv_157" class="t s4_157">create two plans, one irradiating widely to a low dose and one boosting </span>
<span id="tw_157" class="t s4_157">specific areas to a higher dose; the boost plan may be delivered after </span>
<span id="tx_157" class="t s4_157">completion of the initial plan, or the two plans may be delivered on the </span>
<span id="ty_157" class="t s4_157">same day as separate fractions in twice-daily schemas (see </span><span id="tz_157" class="t s6_157">Principles of </span>
<span id="t10_157" class="t s6_157">Radiation Techniques </span><span id="t11_157" class="t s4_157">in the NCCN Guidelines for Head and Neck </span>
<span id="t12_157" class="t s4_157">Cancers). </span>
<span id="t13_157" class="t s5_157">150,197,202,203 </span>
<span id="t14_157" class="t s4_157">A meta-analysis including seven studies (n = 1049) </span>
<span id="t15_157" class="t s4_157">showed no significant difference in survival outcomes or grade 3 or higher </span>
<span id="t16_157" class="t s4_157">adverse events between SIB-IMRT and sequential boost-IMRT. </span>
<span id="t17_157" class="t s5_157">204 </span>
<span id="t18_157" class="t s4_157">IMRT is now widely used in H&amp;N cancers and is the predominant </span>
<span id="t19_157" class="t s4_157">technique used at NCCN Member Institutions. </span>
<span id="t1a_157" class="t s5_157">205,206 </span>
<span id="t1b_157" class="t s4_157">OS may be similar </span>
<span id="t1c_157" class="t s4_157">between patients treated with IMRT and those receiving conventional 3D- </span>
<span id="t1d_157" class="t s4_157">RT, </span>
<span id="t1e_157" class="t s5_157">187,207-209 </span>
<span id="t1f_157" class="t s4_157">but both are superior to older 2D techniques. For example, a </span>
<span id="t1g_157" class="t s4_157">prospective Korean study showed that 3D and IMRT techniques were </span>
<span id="t1h_157" class="t s4_157">superior to 2D radiation for both PFS and OS in patients with NPC, and </span>
<span id="t1i_157" class="t s4_157">IMRT was associated with improved survival in multivariate analysis, </span>
<span id="t1j_157" class="t s4_157">particularly in T3–T4 tumors. </span>
<span id="t1k_157" class="t s5_157">210 </span>
<span id="t1l_157" class="t s4_157">However, IMRT has been clearly proven to </span>
<span id="t1m_157" class="t s4_157">reduce long-term toxicities. Xerostomia is a common long-term side effect </span>
<span id="t1n_157" class="t s4_157">of RT, which is ameliorated most commonly by use of IMRT, or from </span>
<span id="t1o_157" class="t s4_157">application of drug therapy (eg, pilocarpine, cevimeline), salivary </span>
<span id="t1p_157" class="t s4_157">substitutes, and other novel approaches (eg, surgical relocation of </span>
<span id="t1q_157" class="t s4_157">submandibular gland). </span>
<span id="t1r_157" class="t s5_157">192,211-215 </span>
<span id="t1s_157" class="t s4_157">Importantly, xerostomia has decreased due </span>
<span id="t1t_157" class="t s4_157">to the transition from older 2D and 3D radiotherapy techniques to </span>
<span id="t1u_157" class="t s4_157">IMRT. </span>
<span id="t1v_157" class="t s5_157">187,189 </span>
<span id="t1w_157" class="t s4_157">Numerous phase II and III studies show that IMRT decreases </span>
<span id="t1x_157" class="t s4_157">late toxicity (xerostomia) without compromising tumor control for </span>
<span id="t1y_157" class="t s4_157">nasopharyngeal, oropharyngeal, sinonasal, and other sites. </span>
<span id="t1z_157" class="t s4_157">Multiple randomized phase III trials support the clinical benefits of IMRT in </span>
<span id="t20_157" class="t s4_157">H&amp;N cancers with regard to the reduction in xerostomia. Pow et al </span>
<span id="t21_157" class="t s4_157">evaluated treatment of early-stage NPC with conventional RT techniques </span>
<span id="t22_157" class="t s4_157">versus with IMRT. </span>
<span id="t23_157" class="t s5_157">212 </span>
<span id="t24_157" class="t s4_157">The results showed a statistical improvement in </span>
<span id="t25_157" class="t s4_157">salivary flow and in patient-reported QOL parameters. </span>
<span id="t26_157" class="t s5_157">212 </span>
<span id="t27_157" class="t s4_157">In the study by </span>
<span id="t28_157" class="t s4_157">Kam et al, patients with NPC were randomly assigned to either IMRT or </span>
<span id="t29_157" class="t s4_157">conventional 2D-RT. </span>
<span id="t2a_157" class="t s5_157">192 </span>
<span id="t2b_157" class="t s4_157">At 1 year after treatment, patients in the IMRT arm </span>
<span id="t2c_157" class="t s4_157">had significantly lower rates of clinician-rated severe xerostomia than </span>
<span id="t2d_157" class="t s4_157">patients in the 2D-RT arm (39.3% vs. 82.1%; </span><span id="t2e_157" class="t s6_157">P </span><span id="t2f_157" class="t s4_157">= .001). Salivary flow rates </span>
<span id="t2g_157" class="t s4_157">were also higher with IMRT. The mean parotid dose was 32 Gy in the </span>
<span id="t2h_157" class="t s4_157">IMRT group and 62 Gy in the conventional group. Although a trend for </span>
<span id="t2i_157" class="t s4_157">improvement in patient-reported dry mouth was observed after IMRT, </span>
<span id="t2j_157" class="t s4_157">recovery was incomplete and there was no significant difference in </span>
<span id="t2k_157" class="t s4_157">patient-reported outcomes between the two arms. The authors concluded </span>
<span id="t2l_157" class="t s4_157">that other salivary glands may also be important and merit protection. </span>
<span id="t2m_157" class="t s4_157">Finally, data from a phase III randomized trial in the United Kingdom </span>
<span id="t2n_157" class="t s4_157">(PARSPORT) indicate that IMRT decreases xerostomia when compared </span>
<span id="t2o_157" class="t s4_157">with conventional RT in patients with non-NPC cancers. </span>
<span id="t2p_157" class="t s5_157">187 </span>
<span id="t2q_157" class="t s4_157">In this trial, </span>
<span id="t2r_157" class="t s4_157">patients with T1–T4, N0–N3, M0 disease were treated to a total dose of 60 </span>
<span id="t2s_157" class="t s4_157">or 65 Gy in 30 fractions either with conventional RT (ie, parallel opposed </span>
<span id="t2t_157" class="t s4_157">3D technique) or with IMRT; 80 patients with oropharyngeal and 14 </span>
<span id="t2u_157" class="t s4_157">patients with hypopharyngeal tumors were included. Grade 2 or worse </span>
<span id="t2v_157" class="t s7_157">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
